Jazz Pharmaceuticals JAZZ Amortization of capitalized software and acquired intangible assets
Amortization of capitalized software and acquired intangible assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets?
- Jazz Pharmaceuticals (JAZZ) reported amortization of capitalized software and acquired intangible assets of $172.3M in Q1 2026.
- How has Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets changed year-over-year?
- Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets increased by 11.6% year-over-year, from $154.4M to $172.3M.
- What is the long-term trend for Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's amortization of capitalized software and acquired intangible assets has grown at a 5.6% compound annual growth rate (CAGR), from $525.77M to $654.61M.